Triple-negative breast cancer (TNBC) is characterized by the absence of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor-2 (HER2) expression, which results in a lack of effective therapeutic targets and classifies it as the subtype with the poorest prognosis within breast cancer [2]. This evidence concerns the gene ESR1 and breast cancer.